120 related articles for article (PubMed ID: 17324341)
41. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
42. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
43. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
Valtola J; Varmavuo V; Ropponen A; Selander T; Kuittinen O; Kuitunen H; Keskinen L; Vasala K; Nousiainen T; Mäntymaa P; Pelkonen J; Jantunen E
Leuk Lymphoma; 2016 Sep; 57(9):2025-32. PubMed ID: 26763346
[TBL] [Abstract][Full Text] [Related]
44. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[TBL] [Abstract][Full Text] [Related]
45. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
46. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
[TBL] [Abstract][Full Text] [Related]
47. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
48. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.
Holmberg LA; Maloney D; Bensinger W
Clin Lymphoma Myeloma; 2006 Sep; 7(2):135-9. PubMed ID: 17026825
[TBL] [Abstract][Full Text] [Related]
50. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Choi HY; Yong CS; Yoo BK
Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
[TBL] [Abstract][Full Text] [Related]
51. Blood graft composition after plerixafor injection in patients with NHL.
Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
[TBL] [Abstract][Full Text] [Related]
52. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
53. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
54. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
[TBL] [Abstract][Full Text] [Related]
55. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
56. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
57. Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma.
Jonkhoff AR; De Kreuk AM; Franschman G; Van Der Lelie J; Schuurhuis GJ; Dräger AM; Zweegman S; Huijgens PC; Ossenkoppele GJ
Br J Haematol; 2002 Jul; 118(1):90-100. PubMed ID: 12100131
[TBL] [Abstract][Full Text] [Related]
58. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.
Hess DA; Bonde J; Craft TP; Wirthlin L; Hohm S; Lahey R; Todt LM; Dipersio JF; Devine SM; Nolta JA
Biol Blood Marrow Transplant; 2007 Apr; 13(4):398-411. PubMed ID: 17382247
[TBL] [Abstract][Full Text] [Related]
59. [Relationship between the absolute lymphocyte count before or after autologous hematopoietic stem cell transplantation and the prognosis in patients with non-Hodgkin's lymphoma].
Chen J; Wang JM; Zhang WP; Song XM; Qiu HY; Xu XQ; Zhou H; Chen L
Zhonghua Xue Ye Xue Za Zhi; 2010 Aug; 31(8):510-4. PubMed ID: 21122327
[TBL] [Abstract][Full Text] [Related]
60. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
